{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:38:26Z","timestamp":1785163106158,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008544","name":"Korean Dermatological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaad.2025.03.055","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T01:58:20Z","timestamp":1743040700000},"page":"141-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study"],"prefix":"10.1016","volume":"93","author":[{"given":"Won Ji","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Sun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jaad.2025.03.055_bib1","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.03.055_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","article-title":"Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis","volume":"21","author":"Li","year":"2015","journal-title":"J Clin Rheumatol"},{"issue":"21","key":"10.1016\/j.jaad.2025.03.055_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112906","article-title":"The role of inflammation in cardiovascular disease","volume":"23","author":"Henein","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.jaad.2025.03.055_bib4","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3390\/ijms19071890","article-title":"Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases","volume":"19","author":"Arida","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jaad.2025.03.055_bib5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamacardio.2017.1213","article-title":"Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography\/computed tomography","volume":"2","author":"Dey","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jaad.2025.03.055_bib6","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.jid.2021.03.024","article-title":"Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"141","author":"Gonzalez-Cantero","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.055_bib7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.055_bib8","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1038\/s41598-021-87766-y","article-title":"The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study","volume":"11","author":"Hong","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.055_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.02.050","article-title":"The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: an observational cohort study","volume":"79","author":"Wu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.03.055_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.981838","article-title":"Cardiovascular effects of immunosuppression agents","volume":"9","author":"Elezaby","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.jaad.2025.03.055_bib11","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jdv.14951","article-title":"Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis","volume":"32","author":"Wu","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.03.055_bib12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjd.17335","volume":"180","author":"Ellis","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.055_bib13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/07853890.2021.1924395","article-title":"Risk factors for major adverse cardiovascular events after the first acute coronary syndrome","volume":"53","author":"Okkonen","year":"2021","journal-title":"Ann Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.03.055_bib14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.055_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jaad.2025.03.055_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","article-title":"Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis","volume":"84","author":"Langley","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.03.055_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211032444","article-title":"Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs","volume":"13","author":"Chan","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jaad.2025.03.055_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijcard.2018.06.099","article-title":"Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases","volume":"270","author":"Ntusi","year":"2018","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.jaad.2025.03.055_bib19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/jdv.13152","article-title":"Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study","volume":"30","author":"Ahlehoff","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2025.03.055_bib20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/1346-8138.13398","article-title":"Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: a 6-month prospective study","volume":"43","author":"Pina","year":"2016","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.055_bib21","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of Ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.03.055_bib22","article-title":"The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Ni","year":"2024","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.jaad.2025.03.055_bib23","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","article-title":"Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: results from a 76-week phase 2 randomized trial","volume":"9","author":"Mease","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"10230","key":"10.1016\/j.jaad.2025.03.055_bib24","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2025.03.055_bib25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archdermatol.2012.370","article-title":"Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting","volume":"148","author":"Gelfand","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.03.055_bib26","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225005249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225005249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:46:15Z","timestamp":1766112375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225005249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0190962225005249"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.03.055","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.03.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}